New development of lipid-lowering therapy of coronary heart disease: Inclisiran
10.12092/j.issn.1009-2501.2022.04.002
- Author:
Qi WANG
1
;
Yunzeng ZOU
2
Author Information
1. Department of General Medicine, Zhongshan Hospital of Fudan University
2. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
- Publication Type:Journal Article
- Keywords:
Coronary heart disease;
Inclisiran;
Lipid-lowering therapy;
The latest advances
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):365-368
- CountryChina
- Language:Chinese
-
Abstract:
Because of high rate of nonadherence to statins, the subcutaneously injection of Inclisiran therapy intervals are from 3 months to 6 months, which will increase the patients' adherence to the Inclisiran therapy. In this review, we summarize the latest advances of Inclisiran, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Inclisiran. Finally, we discuss the current status of Inclisiran in the clinical works.
